VHB Life Sciences Limited manufactures Methylprednisolone Tablets. VHB Life Sciences Limited has WHO GMP certified facility as well as INVIMA approved facility. Methylprednisolone Tablets are used in the treatment of acute Status Asthmaticus, Hematological Disorders like Immune Thrombocytopenic Purpura, Neurological Disorder like Myasthenia Gravis Multiple Sclerosis, Dermatological Indication like Erythma Multiforme, Steven Johnson Syndrome, Toxic Epidermal Necrolysis, Rheumatic Disorders, and Ophthalmic Disorder-Optic Neuritis. The dosage is 4 to 160 mg per day depending on the clinical response of the patient. Methylprednisolone Tablets bears the brand name Succimed-O.
